The Effect of Bisoprolol on Heart Failure Preserved Ejection Fraction / Hfpef Patient’s Quality Of Life

Background: Global Public Health Burden of Heart Failure reported the growing prevalence of heart failure which is 64.3 million affected in 2020 worldwide with half of the case classified as Heart Failure Preserved Ejection Fraction (HFpEF). It is well known that someone who has been diagnosed with heart failure will have a poorer 􏰼􏰞􏰏􏰦􏰝􏰊􏰗 􏰓􏰒 􏰦􏰝􏰒􏰋􏰷􏰽􏰓􏰬􏰣 􏰾􏰘􏰖􏰦􏰓􏰩􏰿􏰋􏰑 􏰝􏰌 􏰏 􏰜􏰋􏰏􏰑􏰊 􏰑􏰏􏰊􏰋 􏰦􏰓􏰎􏰋􏰑􏰝􏰚􏰟 􏰏􏰟􏰋􏰚􏰊 􏰎􏰝􏰊􏰜 􏰏 􏰐􏰓􏰊􏰋􏰚􏰩􏰗 􏰊􏰓 􏰝􏰔􏰐􏰑􏰓􏰻􏰋 􏰊􏰜􏰋 􏰐􏰏􏰊􏰝􏰋􏰚􏰊􏱀􏰌 􏰩􏰦􏰝􏰚􏰝􏰩􏰏􏰦 outcomes, one of them is QoL. Objective􏱁 􏰥􏰜􏰝􏰌 􏰌􏰊􏰞􏰕􏰗 􏰏􏰝􏰔􏰋􏰕 􏰊􏰓 􏰓􏰖􏰌􏰋􏰑􏰻􏰋 􏰏􏰚􏰕 􏰋􏰻􏰏􏰦􏰞􏰏􏰊􏰋 􏰊􏰜􏰋 􏰋􏰒􏰒􏰋􏰩􏰊 􏰓􏰒 􏰖􏰝􏰌􏰓􏰐􏰑􏰓􏰦􏰓􏰦􏰳 􏰏 􏰊􏰗􏰐􏰋 􏰓􏰒 􏰾􏰘􏰖􏰦􏰓􏰩􏰿􏰋􏰑􏰳 􏰝􏰚 􏰊􏰜􏰋 􏰝􏰔􏰐􏰑􏰓􏰻􏰋- 􏰔􏰋􏰚􏰊 􏰓􏰒 􏱂􏱃􏰐􏰺􏱃 􏰐􏰏􏰊􏰝􏰋􏰚􏰊􏱀􏰌 􏰽􏰓􏰬􏰣 Method: This study is a retrospective cohort following HFpEF patients who received bisoprolol and HFpEF patients who did not receive bisoprolol. The study participants were selected using purposive sampling method. Result: Our study found that from all HFpEF patients who received bisoprolol 102 patients had a good QoL and 2 patients had a poor QoL (p=0.000) according to Minnesota Living With Heart Failure Questionnaire (MLHFQ). The median physical score in the patient who did not receive bisoprolol was 10 while the median score of the 􏰐􏰏􏰊􏰝􏰋􏰚􏰊 􏰎􏰜􏰓 􏰑􏰋􏰩􏰋􏰝􏰻􏰋􏰕 􏰾􏰘􏰖􏰦􏰓􏰩􏰿􏰋􏰑 􏰎􏰏􏰌 􏰲 􏰪􏰐􏰡􏰢􏰣􏰢􏰢􏰢􏰮􏰣 􏰥􏰜􏰋 􏰔􏰋􏰏􏰚 􏰋􏰔􏰓􏰊􏰝􏰓􏰚􏰏􏰦 􏰌􏰩􏰓􏰑􏰋 􏰒􏰓􏰑 􏰊􏰜􏰋 􏰐􏰏􏰊􏰝􏰋􏰚􏰊􏰌 􏰎􏰜􏰓 􏰕􏰝􏰕 􏰚􏰓􏰊 􏰑􏰋􏰩􏰋􏰝􏰻􏰋 􏰾􏰘􏰖􏰦􏰓􏰩􏰿􏰋􏰑 􏰎􏰏􏰌 􏰸 􏰎􏰜􏰝􏰦􏰋 􏰊􏰜􏰋 􏰔􏰋􏰏􏰚 􏰌􏰩􏰓􏰑􏰋 􏰓􏰒 􏰊􏰜􏰋 􏰐􏰏􏰊􏰝􏰋􏰚􏰊􏰌 􏰎􏰜􏰓 􏰑􏰋􏰩􏰋􏰝􏰻􏰋􏰕 􏰾􏰘􏰖􏰦􏰓􏰩􏰿􏰋􏰑 􏰎􏰏􏰌 􏱄 􏰪􏰐􏰡􏰢􏰣􏰢􏰢􏰢􏰮􏰣 Conclusion􏱁 􏰛􏰋 􏰩􏰓􏰚􏰩􏰦􏰞􏰕􏰋 􏰊􏰜􏰏􏰊 􏰊􏰜􏰋 􏰞􏰌􏰋 􏰓􏰒 􏰖􏰝􏰌􏰓􏰐􏰑􏰓􏰦􏰓􏰦 􏰩􏰓􏰞􏰦􏰕 􏰝􏰔􏰐􏰑􏰓􏰻􏰋 􏰊􏰜􏰋 􏱂􏱃􏰐􏰺􏱃 􏰐􏰏􏰊􏰝􏰋􏰚􏰊􏱀􏰌 􏰽􏰓􏰬 􏰋􏰻􏰏􏰦􏰞􏰏􏰊􏰋􏰕 􏰖􏰗 􏰊􏰓􏰊􏰏􏰦 score, physical score, and emotional score.

Download Full-text

Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity

European Journal of Heart Failure ◽

10.1002/ejhf.1788 ◽

2020 ◽

Vol 22 (6) ◽

pp. 1009-1018 ◽

Cited By ~ 7

Author(s):

Yogesh N.V. Reddy ◽

Aruna Rikhi ◽

Masaru Obokata ◽

Sanjiv J. Shah ◽

Gregory D. Lewis ◽

...

Keyword(s):

Quality Of Life ◽

Heart Failure ◽

Ejection Fraction ◽

Functional Capacity ◽

Physical Inactivity ◽

Preserved Ejection Fraction

Download Full-text

Influence of baseline parameters on one‐year physical, mental, and health‐related quality of life in patients with heart failure and preserved ejection fraction

ESC Heart Failure ◽

10.1002/ehf2.13593 ◽

2021 ◽

Author(s):

Judith Fitz ◽

Frank Edelmann ◽

Gerd Hasenfuß ◽

Anja Sandek ◽

Kathleen Nolte ◽

...

Keyword(s):

Quality Of Life ◽

Heart Failure ◽

Ejection Fraction ◽

Preserved Ejection Fraction ◽

Health Related Quality ◽

Patients With Heart Failure ◽

Related Quality ◽

Health Related ◽

One Year

Download Full-text

Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies

Annual Review of Medicine ◽

10.1146/annurev-med-042220-022745 ◽

2021 ◽

Vol 73 (1) ◽

Author(s):

Kazunori Omote ◽

Frederik H. Verbrugge ◽

Barry A. Borlaug

Keyword(s):

Heart Failure ◽

Ejection Fraction ◽

Treatment Strategies ◽

Annual Review ◽

Publication Date ◽

Preserved Ejection Fraction ◽

Reduced Ejection Fraction ◽

Patients With Heart Failure ◽

Prevalence Of Obesity

Approximately half of all patients with heart failure (HF) have a preserved ejection fraction, and the prevalence is growing rapidly given the aging population in many countries and the rising prevalence of obesity, diabetes, and hypertension. Functional capacity and quality of life are severely impaired in heart failure with preserved ejection fraction (HFpEF), and morbidity and mortality are high. In striking contrast to HF with reduced ejection fraction, there are few effective treatments currently identified for HFpEF, and these are limited to decongestion by diuretics, promotion of a healthy active lifestyle, and management of comorbidities. Improved phenotyping of subgroups within the overall HFpEF population might enhance individualization of treatment. This review focuses on the current understanding of the pathophysiologic mechanisms underlying HFpEF and treatment strategies for this complex syndrome. Expected final online publication date for the Annual Review of Medicine, Volume 73 is January 2022. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

Download Full-text

Association of long-term SBP with clinical outcomes and quality of life in heart failure with preserved ejection fraction

Journal of Hypertension ◽

10.1097/hjh.0000000000002807 ◽

2021 ◽

Vol Publish Ahead of Print ◽

Author(s):

Peisen Huang ◽

Yuan Yu ◽

Fangfei Wei ◽

Wengen Zhu ◽

Ruicong Xue ◽

...

Keyword(s):

Quality Of Life ◽

Heart Failure ◽

Ejection Fraction ◽

Clinical Outcomes ◽

Preserved Ejection Fraction

Download Full-text

Exercise Training Improved Longitudinal Intrinsic Left Ventricle Function in Heart Failure with Preserved Ejection Fraction

International Journal of Angiology ◽

10.1055/s-0038-1676836 ◽

2019 ◽

Vol 28 (01) ◽

pp. 044-049

Author(s):

Sidhi Purwowiyoto ◽

Budhi Purwowiyoto ◽

Amiliana Soesanto ◽

Anwar Santoso

Keyword(s):

Quality Of Life ◽

Heart Failure ◽

Exercise Training ◽

Ejection Fraction ◽

Left Ventricular ◽

World Health ◽

Volume Index ◽

Lv Function ◽

Preserved Ejection Fraction

Exercise improves morbidity, fatality rate, and quality of life in heart failure with low ejection fraction, but fewer data available in heart failure with preserved ejection fraction (HFPEF).The purpose of this study is to test the hypothesis that exercise training might improve the longitudinal intrinsic left ventricular (LV) function in HFPEF patients.This quasi-experimental study had recruited 30 patients with HFPEF. Exercise training program had been performed for a month with a total of 20 times exercise sessions and evaluated every 2 weeks. Echocardiography was performed before sessions, second week and fourth week of exercise training. Six-minute walk tests (6MWTs) and quality-of-life variables using Minnesota living with HF scoring and the 5-item World Health Organization Well-Being Index scoring were measured before and after exercise as well.Left ventricular filling pressure, represented by the ratio of early diastolic mitral flow velocity/early diastolic annular velocity and left atrial volume index, improved during exercise. The longitudinal intrinsic LV function, represented by four-chamber longitudinal strain, augmented during exercise (p < 0.001). Aerobic capacity, measured by 6MWT, increased significantly (p = 0.001). Quality of life improved significantly during exercise (p < 0.001).Exercise training was suggested to improve the longitudinal intrinsic LV function and quality of life in HFPEF. Clinical Trial Registration: ACTRN12614001042639.

Download Full-text

GW29-e0618 A Meta-analysis of the effect of exercise training on exercise capacity and quality of life in patients with heart failure with preserved ejection fraction.

Journal of the American College of Cardiology ◽

10.1016/j.jacc.2018.08.1021 ◽

2018 ◽

Vol 72 (16) ◽

pp. C239

Author(s):

Lingling Wu ◽

Yingying Zheng ◽

PengYang Li ◽

Jiangui He

Keyword(s):

Quality Of Life ◽

Heart Failure ◽

Exercise Training ◽

Ejection Fraction ◽

Exercise Capacity ◽

Meta Analysis ◽

Preserved Ejection Fraction ◽

Patients With Heart Failure

Download Full-text

P322Inhibitors of the renin-angiotensin system in diabetic patients with heart failure with preserved ejection fraction treatment: impact of m235t polymorphism of angiotensinogen

European Heart Journal ◽

10.1093/eurheartj/ehz747.0157 ◽

2019 ◽

Vol 40 (Supplement_1) ◽

Author(s):

O Medentseva ◽

I S Rudyk ◽

M M Udovychenko ◽

I C Gasanov ◽

D P Babichev ◽

...

Keyword(s):

Heart Failure ◽

Blood Pressure ◽

Ejection Fraction ◽

Renin Angiotensin System ◽

Diabetic Patients ◽

Preserved Ejection Fraction ◽

Angiotensin System ◽

Patients With Heart Failure ◽

Heart Failure Questionnaire ◽

M235t Polymorphism

Abstract Background Inhibitors of the renin-angiotensin system plays an important role in chronic heart failure treatment. However, the impact of Angiotensin-converting enzyme (ACE) inhibitors and Angiotensin II receptor blockers (ARBs) on treatment efficacy in diabetic patients with heart failure with preserved preserved ejection fraction (HFpEF) depending on M235T polymorphism of ATG is still unknown. Aim To estimate the efficacy of ACE inhibitors and ARBs therapy in diabetic patient with HFpEF depending on the polymorphism of the M235T of the ATG gene. Methods A total of eighty-two patients (50 females and 32 males; mean age 62,9±8,1 years) with HFpEF and type 2 diabetes mellitus were examined. Sixty-two patients were carriers of 235T allele (MT+TT genotypes), 20 patients had MM genotype of M235T polymorphism of ATG, which was determined by using of polymerase chain reaction. All patients were divided into 4 groups depending on genotypes taking Ramipril or Valsartan during 12 months. Clinical examination, 6 minute walking test, Minnesota Living with Heart Failure Questionnaire (MLHFQ) have been used. All statistical tests were 2-tailed and p<0,05 was considered statistically significant and performed in Statistica 10.0. Results It was not found the significant difference in efficacy of treatment using Valsartan or Ramipril in diabetic patients with genotype MM with HFpEF, whereas in the presence of the T allele of the polymorphism of the M235T ATG, use of valsartan was more effective. Table shows the dynamics of the investigated parameters. Dynamics of parametrs during treatment Parameters HFpEF and DM2T, TT or MT HFpEF and DM2T, MM Ramipril (n=22) Valsartan (n=21) Ramipril (n=10) Valsartan (n=10) Baseline After 12 months treatment Baseline After 12 months treatment Baseline After 12 months treatment Baseline After 12 months treatment SBP, mm Hg 172.0 [157.2; 178.5] 150.0 [132.0; 152.0]* 165.0 [145.3; 174.2] 128.0 [126.0; 134.0]* 167,5 [152.5; 176.0] 140.0 [134.0; 142.0] 160,0 [144.0; 170.0] 146.0 [138.0; 150.0] DBP, mm Hg 98.0 [86.0; 104.0] 92.0 [80.0; 94.0]* 96.0 [82.0; 100.0] 86.0 [80.0; 88.0]* 102.0 [84.0; 106.0] 98.0 [84.0; 100.0] 99.0 [80.0; 100.0] 94.0 [80.0; 96.0] 6 min test, m 313,0 [226,7; 375,5] 320,0 [236,4; 384,6]* 342.5 [258.0; 393.7] 372,0 [262,7; 397,9]* 305.0 [190.5; 375.0] 315.0 [198.5; 384.0] 328.0 [295.0; 401.0] 342.0 [298.0; 410.0] MLHFQ 62,0 [50,0; 71,2] 56,0 [46,5; 68,4]* 61.5 [50.5; 71.5] 40.5 [36.5; 56.5]* 60.0 [47.0; 76.2] 54.0 [43.0; 70.0] 58.0 [49.5; 76.2] 58.0 [49.5; 76.2] Dispnea, % 100 90* 100 70* 100 90 100 80 Edema, % 68,1 54,5* 61,9 33,3* 50 40 60 60 SBP, systolic blood pressure; DBP, diastolic blood pressure; MLHFQ, Minnesota Living with Heart Failure Questionnaire; statistically significant changes (p<0.05). Conclusion Use of Valsartan comparing to Ramipril in diabetic T allele carriers of M235T polymorphism of ATG with HFpEF was independently associated with more effective clinical signs of heart failure improvement, blood pressure decrease, quality of life according to the MLHFQ and physical activity tolerance increase.

Download Full-text